agree, but its all those nasty expenses associated with their strategy.
Thats the pesky things with companies you have to look at both sides of the ledger
Just doesnt look good when you do that, thats why the auditor had issues with this being a going concern.
They didnt seem to think the growing revenue was enough.
Why would that be?
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-73
-
- There are more pages in this discussion • 495 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |